Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab (SLK) [8] - The lawsuit claims that MoonLake promoted SLK as superior to competing drugs while failing to disclose its lack of proven superiority [8] - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price dropped nearly 90%, resulting in significant investor losses [8] Allegation Details - The lawsuit alleges that MoonLake and its executives misrepresented the clinical advantages of SLK, which was claimed to have a unique Nanobody structure [8] - It is claimed that SLK targeted the same molecules as UCB's BIMZELX, contradicting the company's assertions of superiority [8] - The stock price fell 89.9% on September 29, 2025, after the announcement of the Phase 3 trial results [8] Next Steps - Investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, are encouraged to contact the law firm for more information and to discuss their legal rights [4] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [8]

Core Points - The Lead Plaintiff Deadline for the securities class action lawsuit against MoonLake Immunotherapeutics is December 15, 2025 [1] - The lawsuit claims that MoonLake and certain executives made materially false and misleading statements about the clinical prospects of their lead drug candidate, sonelokimab (SLK) [1] - The alleged misleading statements resulted in a significant stock price decline for MoonLake [1]

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a legal deadline for investors to act by December 15, 2025 [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [5]. Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data and the advantages of SLK's Nanobody structure compared to traditional monoclonal antibody treatments, which may have misled investors regarding the drug's regulatory approval and commercial viability [6][7]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in recent years [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics centers on allegations that the company misrepresented the clinical efficacy of its Nanobody structure compared to traditional monoclonal antibodies, particularly in the context of the Phase 3 VELA trials [2][3]. Legal Allegations - The lawsuit claims that MoonLake failed to disclose that its product SLK shares the same molecular targets as BIMZELX, a competitor, which undermines its claimed competitive advantage [3]. - Allegations include that the company misrepresented the Nanobody's ability to provide superior clinical efficacy, specifically in treating hidradenitis suppurativa [3]. - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these issues [3]. Financial Impact - Investors who purchased MLTX shares during the Class Period (March 10, 2024, through September 29, 2025) and experienced significant losses are encouraged to participate in the lawsuit [4]. - Hagens Berman has a history of securing over $2.9 billion in settlements for investors in similar cases, indicating a strong potential for recovery [4][7]. Next Steps for Investors - The deadline for investors to move for appointment as lead plaintiff in the class action lawsuit is December 15, 2025 [1][5]. - Investors are urged to contact Hagens Berman for more information and to discuss their losses related to MoonLake [5][6].

Core Viewpoint - Holzer & Holzer, LLC is reminding investors of deadlines to seek lead plaintiff status in several class action lawsuits against companies including MoonLake Immunotherapeutics, DexCom, and Synopsys, alleging misleading statements and failure to disclose material facts during specified periods [1][2][3]. Group 1: MoonLake Immunotherapeutics (MLTX) - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company made materially false and/or misleading statements regarding SLK's superiority to monoclonal antibodies between March 10, 2024, and September 29, 2025 [1]. - Investors who purchased shares during this period and suffered significant losses are encouraged to discuss their legal rights [1]. Group 2: DexCom, Inc. (DXCM) - A class action lawsuit has been filed against DexCom, alleging that the company made materially false and/or misleading statements regarding design changes to its G6 and G7 products between January 8, 2024, and September 17, 2025 [2]. - Investors who purchased shares during this period and suffered significant losses are encouraged to discuss their legal rights [2]. Group 3: Synopsys, Inc. (SNPS) - A class action lawsuit has been filed against Synopsys, alleging that the company made materially false and/or misleading statements regarding the economics of its Design IP business between December 4, 2024, and September 9, 2025 [3]. - Investors who purchased shares during this period and suffered significant losses are encouraged to discuss their legal rights [3]. Group 4: Holzer & Holzer, LLC - Holzer & Holzer, LLC is recognized as a top-rated securities litigation law firm and has been involved in recovering hundreds of millions of dollars for shareholders affected by fraud and corporate misconduct since its founding in 2000 [4]. - The firm is dedicated to representing shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, highlighting its expertise in complex securities cases [4].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with investors having until December 15, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically targeting moderate to severe hidradenitis suppurativa with its investigational drug sonelokimab [3][4]. - The company previously claimed that its clinical data indicated a superior clinical benefit and differentiation of sonelokimab compared to competitors [4]. Group 3: Clinical Trial Results - The Phase 3 VELA trials for sonelokimab reported disappointing results, with VELA-2 failing to meet its primary endpoint, raising concerns about the drug's regulatory approval and commercial viability [5][6]. - Following the announcement of the trial results on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - The Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, which led to investor damages when the truth was revealed [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in recent years [5].